Skip to main content
. 2022 Nov 18;13:1017889. doi: 10.3389/fphar.2022.1017889

FIGURE 2.

FIGURE 2

Information component and its 95% credibility interval over time for different types of anti-VEGF-associated ocular adverse events. Abbreviations: ●, Ranibizumab; ■, Aflibercept; ▲, Brolucizumab; IC, information component; CI, credibility interval. The error bars show the 95% credibility interval (CI) of the information component (IC), when the IC curve is steady upward trend and the 95% CI narrowed, the signal is stable and strong association.